Sarepta

News

Third death reported with a Sarepta gene therapy

A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles being faced by the company.

News

FDA probing deaths with DMD gene therapy Elevidys

The FDA has launched a formal investigation into two liver failure-related deaths in patients treated with Duchenne gene therapy Elevidys.

News

DMD gene therapy Elevidys linked to new liver failure case

Another death from liver failure has been seen with Roche and Sarepta's Duchenne muscular dystrophy therapy Elevidys, prompting a pause on treatment.

News

Multiple studies of Sarepta's DMD therapy halted after death

Three studies of Sarepta's Elevidys Duchenne gene therapy have been placed on hold as the death of a 16-year-old boy is investigated.

News

Sarepta slumps on Elevidys patient death

The death of a patient treated with Sarepta's Duchenne muscular dystrophy gene therapy Elevidys has hit its share price.

News

Sarepta pulls plug on Duchenne exon-skipping drug

Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.

Third death reported with a Sarepta gene therapy

FDA probing deaths with DMD gene therapy Elevidys

DMD gene therapy Elevidys linked to new liver failure case

Multiple studies of Sarepta's DMD therapy halted after death

Sarepta slumps on Elevidys patient death

Sarepta pulls plug on Duchenne exon-skipping drug

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

Sarepta

Editor's Picks